Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
13.55
+7.99 (143.71%)
At close: Nov 20, 2024, 4:00 PM
12.31
-1.24 (-9.15%)
Pre-market: Nov 21, 2024, 4:35 AM EST

Forte Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Selling, General & Admin
16.110.628.37.634.221.38
Upgrade
Research & Development
19.5321.865.5913.85102.68
Upgrade
Operating Expenses
35.6332.4913.921.4914.234.06
Upgrade
Operating Income
-35.63-32.49-13.9-21.49-14.23-4.06
Upgrade
Interest & Investment Income
1.121.120.16---
Upgrade
Other Non Operating Income (Expenses)
0.31-0.11-0.15-0.22-0.21-0.01
Upgrade
EBT Excluding Unusual Items
-34.2-31.48-13.88-21.71-14.43-4.07
Upgrade
Pretax Income
-34.2-31.48-13.88-21.71-46.49-4.07
Upgrade
Net Income
-34.2-31.48-13.88-21.71-46.49-4.07
Upgrade
Net Income to Common
-34.2-31.48-13.88-21.71-46.49-4.07
Upgrade
Shares Outstanding (Basic)
211100
Upgrade
Shares Outstanding (Diluted)
211100
Upgrade
Shares Change (YoY)
82.51%81.61%24.45%89.81%249.05%-76.47%
Upgrade
EPS (Basic)
-18.53-24.92-19.96-38.85-157.93-48.25
Upgrade
EPS (Diluted)
-18.53-24.92-19.96-38.85-157.93-48.25
Upgrade
Free Cash Flow
-29.73-28.79-8.19-16.68-18.42-2.93
Upgrade
Free Cash Flow Per Share
-16.11-22.80-11.77-29.85-62.59-34.78
Upgrade
EBITDA
-35.6-32.48-13.86-21.45-14.17-4.05
Upgrade
D&A For EBITDA
0.040.010.040.040.050.01
Upgrade
EBIT
-35.63-32.49-13.9-21.49-14.23-4.06
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.